References

  1. Mylan data on file (myl_xen_dof_v1).
  2. Xenidate XL. Summary of Product Characteristics (SPC) – all doses. April 2017.
  3. NICE. Methylphenidate hydrochloride. https://bnf.nice.org.uk/medicinal-forms/methylphenidate-hydrochloride.html (last accessed 27.09.18).
  4. Mylan data on file (tablet sizes).
  5. NICE Clinical Knowledge Summaries. Attention deficit hyperactivity disorder.
    https://cks.nice.org.uk/attention-deficit-hyperactivity-disorder#!topicsummary (last accessed 11.10.18).
  6. Holden SE et al. The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). Child and Adolescent Psychiatry and Mental Health 2013;7:34.
  7. Xenidate XL. Patient Information Leaflets – all doses. April 2017.
  8. NHS. Symptoms: Attention deficit hyperactivity disorder (ADHD).
    https://www.nhs.uk/conditions/attentiondeficit- hyperactivity-disorder-adhd/symptoms/ (last accessed 09.10.18).
  9. NICE guideline 87. Attention deficit hyperactivity disorder: diagnosis and management.
    14 March 2018. www.nice.org.uk/guidance/ng87 (last accessed 12.10.18).
  10. NHS England. Medicines Value Programme.
    https://www.england.nhs.uk/medicines/value-programme/ (last accessed 12.20.18).